AtheroGenics, Inc.

AtheroGenics, Inc.

March 19, 2007 06:31 ET

AtheroGenics Announces Conference Call to Provide Business Update

Conference Call Is Scheduled at 8:30 a.m. EDT on Monday, March 19, 2007

ATLANTA, GA--(CCNMatthews - March 19, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX) announced that it will hold a conference call today in which it will provide a business update to investors.

"Based on our review of the ARISE clinical trial results, we are optimistic about the therapeutic potential of AGI-1067 and currently intend to continue its development with the goal of improving patient care," commented Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics. "We will continue to analyze the extensive body of data generated by this trial and meet with regulatory agencies in order to select the optimal development path for the compound."

"We believe that the strength of our financial position and the capabilities of our dedicated team of professionals at AtheroGenics place us in a strong position to continue development of AGI-1067," concluded Dr. Medford.

Conference Call

To participate in the conference call, please dial 877-407-8031 for domestic callers and 201-689-8031 for international callers. A replay of the conference call will be available until March 26, 2007 at 11:59 p.m. To access the replay, please dial 877-660-6853 for domestic callers and 201-612-7415 for international callers, and reference Account #286 and Conference ID# 216271.

In addition, this call can be accessed via webcast at

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. AtheroGenics and AstraZeneca have a worldwide collaboration covering the development and commercialization of AGI-1067. In addition to AGI-1067, the Company has another clinical-stage development program studying AGI-1096, a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit

Disclosure Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve significant risks and uncertainties, including preliminary summary statements relating to the analysis of AtheroGenics' ARISE study for AGI-1067 and preliminary summary statements relating to the potential efficacy and safety profile of AGI-1067. These and other statements contained in this press release that relate to events or developments that we expect or anticipate will occur in the future are deemed to be forward-looking statements, and can be identified by words such as "believes," "intends," "expects" and similar expressions. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. AtheroGenics cautions investors not to place undue reliance on the forward-looking statements contained in this release. The preliminary results discussed in this release may not be confirmed upon full analysis of the detailed results of the ARISE study and additional information relating to the safety, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. In addition, our forward-looking statements are subject to a number of factors that could cause actual outcomes to differ materially from those expressed or implied in our forward-looking statements, including that the Food and Drug Administration might not allow us to conduct further studies of the efficacy of AGI-1067 for the same or new endpoints, and, to the extent approved, additional clinical trial work may take a significant period of time to complete or require significant additional resources to complete, or that AstraZeneca could terminate its collaboration agreement with us based on the results of the clinical trial. We cannot ensure that AGI-1067 will ever be approved or be proven safe and effective for use in humans. These and other risks are discussed in AtheroGenics' Securities and Exchange Commission filings, including, but not limited to, the risks discussed in AtheroGenics' Annual Report on Form 10-K for the fiscal year ended December 31, 2006. The risk factors regarding AtheroGenics that are included under the caption "Risk Factors" in AtheroGenics' Annual Report on Form 10-K for the fiscal year ended December 31, 2006 are specifically incorporated by reference into this press release. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information